Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.

Abstract: The invention provides methods for treating humans in need of combined immunosuppressant and biological response modifier therapy.

Abstract: The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.

Abstract: The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.

Abstract: The present invention provides compositions and their use in diagnosing ulcerative colitis, Crohn's Disease, and inflammatory bowel disease.

Abstract: Pharmacogenetic methods for determining a predicting responsiveness to antifolate therapy for subjects that present with recent-onset undifferentiated arthritis. The methods are based on the determination of a set of clinical parameter values and determining a predicted responsiveness to antifolate therapy by correlating the parameter values with predefined responsiveness values associated with ranges of parameter values. Parameters values that are decisive for responsiveness to antifolate therapy may include polymorphisms in the methylenetetrahydrofolate dehydrogenase (MTHFD1) gene as well as in three genes involved in the adenosine release pathway, the presence or absence of Rheumatoid factors, gender, pre- or postmenopausal status and/or smoking status.

Abstract: The present invention provides a method for efficiently converting methotrexate polyglutamates to methotrexate in a cellular extract by contacting the cellular extract with gamma glutamyl hydrolase under conditions suitable for efficient conversion of methotrexate polyglutamates to methotrexate.

Abstract: The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.

Abstract: The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.

Abstract: The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.

Abstract: The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome.

Abstract: Methods and devices, including methods and devices for estimating classifier performance such as generalization performance, are disclosed. One method includes providing multiple samples. Each sample is characterized by one or more features. This method also includes associating a feature variability with at least one of the one or more features on a feature-by-feature basis; and computing a first probability of misclassification by a first classifier using the feature variability. Devices, including integrated circuits (ICs) and field programmable gate arrays (FPGAs), that are configured for use in carrying out the present methods are also disclosed.

Abstract: The present invention provides novel compositions and their use in classifying acute myelogenous leukemia.

Abstract: The present invention provides novel compositions and their use in classifying gliomas. In a preferred embodiment, the methods are used to discriminate between oligodendroglioma and glioblastoma.

Abstract: Methods and devices, including methods and devices for estimating classifier performance such as generalization performance, are disclosed. One method includes providing multiple samples. Each sample is characterized by one or more features. This method also includes associating a feature variability with at least one of the one or more features; and computing a first probability of misclassification by a first classifier using the feature variability. Devices, including integrated circuits (ICs) and field programmable gate arrays (FPGAs), that are configured for use in carrying out the present methods are also disclosed.

Abstract: The present invention provides novel compositions and their use in classifying acute myelogenous leukemia.

Abstract: The present invention provides novel compositions and their use in classifying gliomas. In a preferred embodiment, the methods are used to discriminate between oligodendroglioma and glioblastoma.

Abstract: The present invention provides novel compositions and their use in classifying acute myelogenous leukemia.

Abstract: The present invention provides improved methods for in situ hybridization (ISH) comprising: (a) obtaining a tissue sample from a subject; (b) contacting the tissue sample with a fixative under conditions to cause fixation of the tissue sample; (c) contacting nucleic acids in the tissue sample with a detectable probe under conditions suitable to promote hybridization of the detectable probe to a target RNA in the tissue sample; (d) removing non-bound probe from the tissue sample; and (e) detecting the probe bound to the target RNA.

Abstract: The present invention provides novel methods for in situ hybridization in the absence of competitor DNA.